Venture Capital: Generate Biomedicines, Which Uses Machine Learning To Invent New Drugs, Raises $370M

Generate Biomedicines is backed by Flagship Pioneering, the investor behind Moderna.

Generate Biomedicines, which uses its machine learning powered Generative Biology platform to make novel proteins with specific therapeutic functions, and thereby invent new drugs at never-before speeds, has raised a $370 million Series B. Investors in the round, which marked Generate’s first outside financing, included founder, Flagship Pioneering, along with several institutional co-investors: a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), the Alaska Permanent Fund, Altitude Life Science Ventures, ARCH Venture Partners, Fidelity Management & Research Company LLC, Morningside Ventures, and funds and accounts advised by T. Rowe Price Associates, Inc. (Boston Globe)

Generate, founded in 2018, previously saw an initial investment of $50 million from Flagship in 2020 on emerging from stealth mode.

It currently has about 80 employees, but is expecting to add more than 400 in the next couple of years. It has under construction two state-of-the-art facilities that will significantly expand the company’s computational biology, machine learning, data generation, and wet lab capabilities.

Drug development – fundamental shift

Generative says it is following a fundamentally different approach to drug development. Rather than legacy trial-and-error methods that depend on what’s taking place in the lab, Generative is using machine learning to enter an era of programmable drug engineering – its horizons are no longer restricted to the existing proteins found in nature – instead the firm can generate entirely novel, de novo proteins that are purpose-built to address an existing or emerging therapeutic need.

“In the future, therapeutic proteins will be generated, rather than discovered,” said Geoffrey von Maltzahn, Ph.D., Co-Founder, Board Member of Generate, and General Partner at Flagship Pioneering. ​“Given the vast number of proteins that could exist, current approaches to protein therapeutic discovery can only tap into a minute subset of possible proteins.

“Our Generative Biology platform gives us the ability to generate de novo, antibodies, peptides, enzymes, cytokines, and other undiscoverable protein therapeutics with optimized functions. This represents a remarkable leap forward in the field of protein therapeutics.”

Related Story: AI Solves 50-Year-Old Biology Mystery; Medical Breakthroughs Could Follow

Image credit: Generate

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
Digital Assets: India To Clamp Down On Cryptocurrencies Via Legislation By Year-End
November 24, 2021     Digital Assets, Latest News, News

The legislative agenda for the upcoming winter session of the Lok Sabha, the lower house of India’s parliament, shows that a bill titled “The Cryptocurrency and Regulation of Official Digital…
FinTech: Klarna Launches “Pay Now” In The US, Klarna Card Soon To Follow
November 24, 2021     FinTech, News

Klarna, the Stockholm-headquartered fintech powerhouse last valued at $45.6 billion, has brought a “Pay Now” offering to consumers at retailers wherever Klarna is accepted. The company also announced a Klarna…
Venture Capital: Agtech And Farmer-To-Farmer Platform FBN Raises $300M
November 24, 2021     ESG and Sustainability, News, Venture Capital

Farmers Business Network (FBN) is a farmer-to-farmer network launched in 2014 as an information source and for sharing of agronomic precision data. It now has thousands of farmer-members managing millions…
Venture Capital: Arc, Which Makes $300K Electric Boats, Snags $30M
November 24, 2021     News, Venture Capital

Arc, a startup led by former SpaceX engineers and developing electric boats, announced its $30 million Series A raise led by Greg Reichow, a former Tesla VP of Production, now…